Literature DB >> 9553063

The crk3 gene of Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 kinase that associates with p12.

K M Grant1, P Hassan, J S Anderson, J C Mottram.   

Abstract

A cdc2-related protein kinase gene, crk3, has been isolated from the parasitic protozoan Leishmania mexicana. Data presented here suggests that crk3 is a good candidate to be the leishmanial cdc2 homologue but that the parasite protein has some characteristics which distinguish it from mammalian cdc2. crk3 is predicted to encode a 35.6-kDa protein with 54% sequence identity with the human cyclin-dependent kinase cdc2 and 78% identity with the Trypanosoma brucei CRK3. The trypanosomatid CRK3 proteins have an unusual, poorly conserved 19-amino acid N-terminal extension not present in human cdc2. crk3 is single copy, and there is 5-fold higher mRNA in the replicative promastigote life-cycle stage than in the non-dividing metacyclic form or mammalian amastigote form. A leishmanial suc-binding cdc2-related kinase (SBCRK) histone H1 kinase, has previously been described which binds the yeast protein, p13(suc1), and that has stage-regulated activity (Mottram J. C., Kinnaird, J., Shiels, B. R., Tait, A., and Barry, J. D. (1993) J. Biol. Chem. 268, 21044-21051). CRK3 from cell extracts of the three life-cycle stages was found to bind p13(suc1) and the leishmanial homologue p12(cks1). CRK3 fused with six histidines at the C terminus was expressed in L. mexicana and shown to have SBCRK histone H1 kinase activity. Depletion of histidine-tagged CRK3 from L. mexicana cell extracts, by Ni-nitrilotriacetic acid agarose selection, reduced histone H1 kinase activity binding to p13(suc1). These data imply that crk3 encodes the kinase subunit of SBCRK. SBCRK and histidine-tagged CRK3 activities were inhibited by the purine analogue olomoucine with an IC50 of 28 and 42 microM, respectively, 5-6-fold higher than human p34(cdc2)/cyclinB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553063     DOI: 10.1074/jbc.273.17.10153

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178.

Authors:  Felipe C Gomes; Nahla Osman M Ali; Elaine Brown; Roderick G Walker; Karen M Grant; Jeremy C Mottram
Journal:  Mol Biochem Parasitol       Date:  2010-03-23       Impact factor: 1.759

2.  Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism.

Authors:  Xiaoming Tu; Ching C Wang
Journal:  Eukaryot Cell       Date:  2005-04

3.  Parallel synthesis of a series of non-functional ATP/NAD analogs with activity against trypanosomatid parasites.

Authors:  Andreas Link; Philipp Heidler; Marcel Kaiser; Reto Brun
Journal:  Mol Divers       Date:  2009-05-30       Impact factor: 2.943

Review 4.  Protein kinases as drug targets in trypanosomes and Leishmania.

Authors:  Christina Naula; Marilyn Parsons; Jeremy C Mottram
Journal:  Biochim Biophys Acta       Date:  2005-09-08

5.  Drug targets in Leishmania.

Authors:  Bhavna Chawla; Rentala Madhubala
Journal:  J Parasit Dis       Date:  2010-10-08

6.  Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity.

Authors:  Karen M Grant; Morag H Dunion; Vanessa Yardley; Alexios-Leandros Skaltsounis; Doris Marko; Gerhard Eisenbrand; Simon L Croft; Laurent Meijer; Jeremy C Mottram
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Emerging therapeutic targets for treatment of leishmaniasis.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Opin Ther Targets       Date:  2018-05-09       Impact factor: 6.902

8.  A potential role for ICP, a Leishmanial inhibitor of cysteine peptidases, in the interaction between host and parasite.

Authors:  Sébastien Besteiro; Graham H Coombs; Jeremy C Mottram
Journal:  Mol Microbiol       Date:  2004-12       Impact factor: 3.501

9.  High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase.

Authors:  Roderick G Walker; Graeme Thomson; Kirk Malone; Matthew W Nowicki; Elaine Brown; David G Blake; Nicholas J Turner; Malcolm D Walkinshaw; Karen M Grant; Jeremy C Mottram
Journal:  PLoS Negl Trop Dis       Date:  2011-04-05

10.  Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi.

Authors:  Marilyn Parsons; Elizabeth A Worthey; Pauline N Ward; Jeremy C Mottram
Journal:  BMC Genomics       Date:  2005-09-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.